ADVFN - Advanced Financial Network.
HOME» NYSE » N » NVS Stock Price » NVS Stock News

Novartis Share News

 Novartis Ag Basel Stock Price
NVS Stock Price
 Novartis Ag Basel Stock Chart
NVS Stock Chart
 Novartis Ag Basel Stock News
NVS Stock News
 Novartis Ag Basel Company Information
NVS Company Information
 Novartis Ag Basel Stock Trades
NVS Stock Trades

Novartis CEO Sees Big Potential In Biosimilars

ZURICH -(Dow Jones)- Novartis AG (NVS) Chief Executive Joe Jimenez said Tuesday he sees potential in the market for biosimilars, cheaper versions of expensive and complex medicines made from biological matter. "This is a market that is relatively small today, but we expect that by 2020 this could be a 15 to 20 billion dollars segment of the generics business," Jimenez told analysts in a call. "Novartis is uniquely positioned in biosimilars because we have the scientific and medical expertise of a pharmaceutical company and the commercial expertise of a generics company," he said. Novartis has its own generics unit, Sandoz. Biosimilars are imitations of biotech drugs, ones that are basically interchangeable with a previously approved biologic but because of the inherent complexity of the products cannot be termed identical. -By Marta Falconi, Dow Jones Newswires; +41 43 443 8043; marta.falconi@dowjones.com

Stock News for Novartis (NVS)
DateTimeHeadline
07/02/201503:48:47Ergomed Appoints Andrew Mackie as Chief Business Officer
06/29/201517:51:48ADRs End Lower; National Bank of Greece Drops Sharply
06/29/201503:39:07Novartis Buys Drug Development Company Spinifex Pharmaceuticals
06/24/201511:22:00Hagens Berman: Class Action Alleges Novartis Gleevec Patent Infringement...
06/22/201518:35:21ADRs End Higher; National Bank of Greece Rises
06/22/201507:47:44GlaxoSmithKline Sells Meningitis Vaccines to Pfizer For EUR115...
06/21/201511:06:03What Is Cancer Immunotherapy?
06/19/201511:38:07Novartis CEO: Roche Stake Would No Longer Have to Be Sold at...
06/18/201518:40:20ADRs End Higher; Telecom Italia Rises
06/18/201515:50:25Teva's Copaxone Patent Loses Again
06/17/201509:04:025 Healthcare Stocks for Dividend Lovers
06/14/201508:03:023 Big Healthcare Trends Wall Street Is Overlooking
06/13/201507:18:021 Drug Will Make or Break These 3 Biotech Stocks
06/10/201510:05:06Cancer Stocks: 2 to Sell, 1 to Buy
06/10/201510:05:06Cancer Stocks: 2 to Sell, 1 to Buy
06/10/201508:04:03Stocks to Watch in Animal Health: Zoetis and WOOF Lead the Pack
06/08/201519:01:02Google Inc Founder Sergey Brin Defends "Moonshots" to Shareholders
06/08/201507:24:023 Big Pharma Dividend Stocks That Are Dragging Down Your Returns
05/31/201513:03:02Stocks To Watch in Biotech
05/31/201510:19:03Why AbbVie, Inc. Is a Better Long-Term Buy Than Gilead Sciences...

Novartis and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad